Copy to clipboard 
Ganymed Robotics, a developer of advanced software and robotics technologies for orthopedic surgeons, raised €21 million (~USD $21.4 million) in the oversubscribed first close of its Series B funding.
Funding will be used to:
- Support Ganymed’s expansion in France and the US
- Finalize the industrial development of its surgical robotic assistant for knee arthroplasty (TKA)
- Accelerate regulatory and marketing developments across geographies
- Diversify the company’s innovation product pipeline
Ganymed Robotics’ technology platform is designed to assist orthopedic surgeons in the OR through its combination of computer vision and mechatronics. The first application is a co-manipulated surgical robotic assistant for TKA.
Ganymed’s device is reportedly the first compact and intuitive robot, fully integrated into the workflow, that simplifies and increases accuracy of orthopedics. In collaboration with clinicians, Ganymed has validated its proprietary algorithms and collected in vivo data via a 100-patient observational study, completed functional prototype tests, initiated industrialization of its first device dedicated to TKA through strategic partnerships with manufacturers and secured a robust patent portfolio.
“The support of this high-profile group of investors, specialized in innovation and healthcare, is a strong endorsement of the work accomplished and of our vision for the future of orthopedic surgery. We are eager to enter this new phase of growth,” says Sophie Cahen, co-founder and CEO of Ganymed Robotics. “With our unique robot-with-eyes platform, we are committed to providing all surgeons and care centers, large and small, with an easy-to-use and cost-effective solution that will radically improve patient outcome, surgeon experience and overall efficiency of joint replacement interventions.”
Source: Ganymed Robotics
Ganymed Robotics, a developer of advanced software and robotics technologies for orthopedic surgeons, raised €21 million (~USD $21.4 million) in the oversubscribed first close of its Series B funding.
Funding will be used to:
Support Ganymed’s expansion in France and the US
Finalize the industrial development of its surgical robotic...
Ganymed Robotics, a developer of advanced software and robotics technologies for orthopedic surgeons, raised €21 million (~USD $21.4 million) in the oversubscribed first close of its Series B funding.
Funding will be used to:
- Support Ganymed’s expansion in France and the US
- Finalize the industrial development of its surgical robotic assistant for knee arthroplasty (TKA)
- Accelerate regulatory and marketing developments across geographies
- Diversify the company’s innovation product pipeline
Ganymed Robotics’ technology platform is designed to assist orthopedic surgeons in the OR through its combination of computer vision and mechatronics. The first application is a co-manipulated surgical robotic assistant for TKA.
Ganymed’s device is reportedly the first compact and intuitive robot, fully integrated into the workflow, that simplifies and increases accuracy of orthopedics. In collaboration with clinicians, Ganymed has validated its proprietary algorithms and collected in vivo data via a 100-patient observational study, completed functional prototype tests, initiated industrialization of its first device dedicated to TKA through strategic partnerships with manufacturers and secured a robust patent portfolio.
“The support of this high-profile group of investors, specialized in innovation and healthcare, is a strong endorsement of the work accomplished and of our vision for the future of orthopedic surgery. We are eager to enter this new phase of growth,” says Sophie Cahen, co-founder and CEO of Ganymed Robotics. “With our unique robot-with-eyes platform, we are committed to providing all surgeons and care centers, large and small, with an easy-to-use and cost-effective solution that will radically improve patient outcome, surgeon experience and overall efficiency of joint replacement interventions.”
Source: Ganymed Robotics
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.
